Publications by authors named "Luke Bamber"

Claim this Profile
P
Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study.
Chi Nguyen, Luke Bamber, Vincent J Willey, Thomas Evers, Thomas P Power

Patient Prefer Adherence· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
Javed Butler, John A Spertus, Luke Bamber, Muhammad Shahzeb Khan, Lothar Roessig

Eur J Heart Fail· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study.
Alexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, Agnes Y Y Lee, Kerstin Folkerts, Luke Bamber

Thromb Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Paul W Armstrong, Carolyn S P Lam, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Luke Bamber

JAMA· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure.
Emi Watanabe-Fujinuma, Hideki Origasa, Luke Bamber, Lothar Roessig, Tetsumi Toyoda

Health Qual Life Outcomes· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials.
Frank Kramer, Javed Butler, Sanjiv J Shah, Christian Jung, Savina Nodari, Luke Bamber

Digit Biomark· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design of the VITALITY-HFpEF Trial.
Javed Butler, Carolyn S P Lam, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Luke Bamber

Circ Heart Fail· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results.
Christoph Gerlinger, Luke Bamber, Friedhelm Leverkus, Carsten Schwenke, Claudia Haberland

BMC Res Notes· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
Gerasimos Filippatos, Aldo P Maggioni, Carolyn S P Lam, Elisabeth Pieske-Kraigher, Javed Butler, Luke Bamber

Eur J Heart Fail· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
Alexander T Cohen, Anja Katholing, Stephan Rietbrock, Luke Bamber, Carlos Martinez

Thromb Haemost· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
Luke Bamber, Dominic Muston, Euan McLeod, Anne Guillermin, Julia Lowin

Thromb J· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Martin H Prins, Luke Bamber, Stefan J Cano, Maria Y Wang, Petra Erkens

Thromb Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Brahim K Bookhart, Lloyd Haskell, Luke Bamber, Maria Wang, Jeff Schein

J Med Econ· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Bonno van Bellen, Luke Bamber, Francine Correa de Carvalho, Martin Prins, Maria Wang

Curr Med Res Opin· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Luke Bamber, Maria Y Wang, Martin H Prins, Cathleen Ciniglio, Rupert Bauersachs

Thromb Haemost· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients.
Stefan J Cano, Donna L Lamping, Luke Bamber, Sarah Smith

Health Qual Life Outcomes· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis